Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Company has 2 marketed drugs that It receives royalties from, 2 more that have an NDA pending ( New Drug Application) 1 drug In stage 3 clinical trials,7 In stage 2 clinical trials,5 In phase 1 clinical trials,and 7 In pre-clinical trials... They have some heavyweight partners as you can see below.
At Ligand, we believe collaboration is an important part of successful drug discovery and development. We have forged numerous valuable research and development alliances with global pharmaceutical companies that have ongoing clinical programs.
Pharmaceutical partnerships include the following companies and span programs in large market indications, such as muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis.
•GlaxoSmithKline
•Wyeth
•Pfizer Inc.
•Bristol-Myers Squibb
•Schering-Plough
•Celgene
•Cephalon
•King Pharmaceuticals
Ligand Is Science
Our research and development programs—both within Ligand and with external partners—are built around our proprietary intracellular (IR) technology. Intracellar technology is the result of our ground-breaking work in the field of gene transcription. It is a powerful technology that has already generated numerous compounds which have advanced to late-stage clinical development.
Ligand Is Success
Ligand has the potential to realize profit streams from milestone and royalty revenues resulting from collaborations with pharmaceutical partners. Recently, we divested commercial assets, allowing us to focus on a business strategy that targets internal research and drug discovery that may provide future licensing opportunities. It seems to me that there are numerous drivers to push this stock In 2010. At a recent $1.93 per share I feel that the possibble upside outweighs the downside risks. Lots to like with such a diverse pipeline,and numerous high profile backers... TS